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Yan-hong Wang1,2, Sheng-long Ye1,2 and Zheng-gang Ren1,2*Abstract
Background: Recent studies suggest that a combination of radiofrequency ablation (RFA) and transarterial
chemoembolization (TACE) may have theoretical advantages over TACE alone for treatment of hepatocellular
carcinoma (HCC). The purpose of this study was to evaluate the effectiveness and safety of radiofrequency ablation
following first-line TACE treatment in the management of HCC beyond the Milan Criteria.
Methods: Forty-five patients who consecutively underwent RFA following first-line TACE treatment for HCC beyond
the Milan criteria were enrolled in this study. RFA was performed within 1–2 months after TACE treatment in
patients who had incomplete necrotic tumor nodules. Primary effectiveness, complications, survival rates, and
prognostic factors were evaluated retrospectively.
Results: Complete ablation was achieved in 76.2% of the lesions according to 1-month follow-up computed
tomography/magnetic resonance imaging evaluation. The mean follow-up period was 30.9 months (range 3–94 months).
There were no major complications after RFA therapy. The median overall survival was 29 months (range 20–38 months),
with 1-, 2-, and 3-year survival of 89%, 61%, and 43%, respectively. Multivariate analysis revealed that tumor diameter
(P = 0.045, hazard ratio [HR] = 0.228, 95% confidence interval [CI]: 0.054-0.968) and pretreatment serum alpha-fetoprotein
level (P = 0.024, HR = 2.239, 95% CI: 1.114-4.500) were independent predictors for long-term survival.
Conclusions: HCC beyond the Milan criteria can be completely and safely ablated by radiofrequency ablation following
first-line TACE treatment with a low rate of complications and favorable survival outcome. Further assessment of the
survival benefits of combination treatment for HCCs beyond the Milan Criteria is warranted.
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Hepatocellular carcinoma (HCC) is the third most common
cause of cancer-related mortality worldwide and the second
most common in China [1,2]. Despite increased early
diagnosis of HCC as a result of surveillance of high-risk
populations, only 30% of patients diagnosed with early
stage HCC are candidates for curative therapies such as* Correspondence: ren.zhenggang@zs-hospital.sh.cn
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reproduction in any medium, provided the orsurgical resection or radiofrequency ablation [3]. Moreover,
the prognosis of patients with advanced or unresectable
HCC remains unsatisfactory due to a low response rate and
short time to progression. According to current treatment
guidelines, transcatheter arterial chemoembolization (TACE)
has been established as the standard therapy for patients
who are not eligible for curative therapies [4,5]. Although
the survival benefit of TACE treatment has been proved
in two randomized clinical trials [5,6], TACE has a pri-
marily palliative effect and does not achieve complete
tumor necrosis therefore tumor relapse after TACE is
universal [7]. Additionally, repetitive TACE treatmentstd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of patients treated with
RFA after first-line treatment with TACE


















<400 ng/ml 25 (55.6)




Tumor diameter with ablation
≤5 cm 44 (52.4)
>5 cm 40 (47.6)
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time. Consequently, new strategies are needed to improve
the effectiveness of TACE treatment for HCC patients.
Percutaneous radiofrequency ablation (RFA) has been
accepted as a curative therapy for small HCC, and can
provide better local control of the disease than TACE
treatment and a similar long-term survival to surgical
resection. Previous studies have shown that RFA can
achieve complete necrosis in more than 90% of small
HCCs [8-10]. Nevertheless, the effectiveness of RFA
treatment in patients with intermediate or large HCC
is unsatisfactory, with a relatively low complete necrosis
rate ranging from 29.0% to 70.0% even if overlapping
ablation or repeated procedures are used [11-13]. There-
fore, conventional RFA treatment was recommended
only for patients with small HCCs confined to the Milan
criteria [14].
Recent evidence has suggested that TACE combined
with RFA may have a synergistic effect on ablation of HCC
[15-17]. To date, few studies have investigated combination
therapy of radiofrequency ablation following transarterial
arterial chemoembolization for patients with unresectable
HCC beyond the Milan criteria. The aim of this study was
to evaluate the effectiveness and safety of such combination
therapy for unresectable HCC.
Methods
Patient enrollment
This survey is a retrospective study in a single center. The
TACE or RFA treatment procedures were according to our
institutional standard treatment protocol at Zhongshan
hospital, Fudan University. The Medical Ethics Committee
of Shanghai Zhongshan Hospital provided ethics approval
for this retrospective study. From February 2001 to November
2009, a total of 611 consecutive HCC patients with unre-
sectable tumors were treated with RFA in the Liver Cancer
Institute, Zhongshan Hospital. All patients had a prospect-
ively established database covering patient demographics,
the etiology of the underlying liver disease, tumor-related
characteristics, serum biochemistries, and survival data.
Patient selection was performed using the following inclu-
sion criteria: (1) diagnosis of HCC confirmed pathologic-
ally or in accordance with American Association for
the Study of Liver Diseases criteria [18]; (2) HCC beyond
the Milan Criteria (single nodule with size ≤5 cm or three
nodules or fewer with tumor size ≤3 cm) that was treated
with TACE as the first-line therapy; (3) tumor nodules
to be ablated should be clearly observed by ultrasound
and there should be no contraindications of RFA therapy;
(4) no portal vein involvement or distant metastasis; (5)
liver function of Child-Pugh A-B; (6) complete clinicopath-
ologic and follow-up data. Ultimately, 45 patients were
included in this study. Patient characteristics are shown
in Table 1.TACE procedure
TACE was performed using a standard procedure. Briefly,
hepatic arteriography was performed to identify the feeding
artery of the liver tumor. The catheter, usually a 4 F or 5 F
RH catheter (Cook Co., USA), was inserted into the tumor
feeding artery as close as possible to the tumor. Micro-
catheters (Terumo Co., Japan) were used to catheterize
the feeding artery if needed. Chemotherapeutic agents
[1000 mg 5-fluoruracil (5-FU), 80 mg cisplatin] were
slowly infused followed by 5–30 ml lipiodol with 10 mg
mitomycin-C emulsion for embolization. The regimen
of chemoembolization was adjusted according to liver
function and peripheral leukocyte or platelet levels. Gelatin
was administered afterwards for additional embolization
in cases with large hypervascular tumors.
RFA procedure
Before RFA treatment, a dynamic contrast computed
tomograph (CT) or magnetic resonance imaging (MRI)
was performed to evaluate the response after TACE
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Disappearance of tumor enhancement in the arterial
phase was considered complete necrosis and identified
tumor nodules that were not targets for RFA. Only tumor
nodules with contrast enhancement in arterial phase with
CT or MRI evaluation were treated with RFA.
From February 2001 to September 2004, 16 patients were
treated with RFA using the RFA 2000 (Radio-Therapeutic,
USA) and a needle electrode with a 15-gauge insulated
cannula and 10 hook-shaped expandable electrode tines
with a diameter of 2.0 or 3.5 cm at expansion (Radio-
Therapeutics,USA). From October 2004 to November
2009, 29 patients were treated with RFA using a 15-gauge
multielectrode RF probe with an expansion of 2.0 or 3.5 cm
(RITA, USA). The details of the treatment procedure are
described in our previous studies [19]. Briefly, RFA was
performed by a percutaneous procedure under conscious
sedation and local anesthesia. The RFA electrode was
inserted into the tumor nodules under the guidance of
ultrasonography. Overlap ablation was allowed to cover the
whole tumor nodule and achieve an adequate safety
margin of 0.5-1.0 cm.
Evaluation of ablation efficiency and follow-up
The ablation efficiency of RFA was evaluated after 1 month
by dynamic contrast-enhanced CT or MRI. Complete ab-
lation (complete response [CR]) was defined as complete
devascularization of the lesions during the arterial phase
and no appearance of new tumors at other liver sites. Pa-
tients were monitored every 2 months after RFA by serum
alpha-fetoprotein (AFP) levels and abdominal ultrasonog-
raphy. Patients with test results suggestive of recurrence
or metastasis received additional computed tomography
and/or magnetic resonance imaging. Patients with local
incomplete ablation or residual disease in the remaining
liver underwent a repeat RFA or chemoembolization.
Statistical analysis
Quantitative variables were expressed as means ± standard
deviation or as medians. Qualitative variables were pre-
sented as numbers and percentages. Student’s t test wasFigure 1 Complete ablation of HCC. A: MRI image before TACE; B: CT imused to compare quantitative variables and the χ2 test
was used for qualitative variables. Overall survival (OS)
was calculated from the date of TACE treatment to death
or the last follow-up. Survival curves were constructed
by the Kaplan-Meier method. Multivariate analysis was
performed using the Cox proportional hazards models.
A difference was considered significant for P <0.05.
Results
Efficiency of ablation
We evaluated a total of 147 tumor nodules in 45 patients
(10 patients with single nodule; 11 with 2 nodules, 2
with 3 nodules, and 22 with 4–5 nodules). Among the 147
nodules, 84 were treated with the RFA procedure. The
other 63 nodules were not treated with RFA because of
complete necrosis presenting with complete lipiodol
deposition and without artery contrast enhancement on
CT or MRI after TACE treatment. For the ablated
tumor lesions, 44 lesions were ≥50 mm and 40 lesions
were <50 mm, with a median tumor diameter of 55.0 mm
(range 20 mm to 80 mm) (Table 1).
Complete ablation was achieved in 64 of 84 (76.2%)
lesions (Figure 1). The remaining 20 (23.8%) lesions were
identified as residual disease attributed to incomplete abla-
tion on CT/MRI images (Figure 2). The ablation efficiency
showed a significant correlation with the size of the lesion:
lesions <50 mm had a higher complete ablation rate than
lesions ≥50 mm with complete ablation rates of 86.4%
(38/44) and 65% (26/40), respectively (P = 0.022). However,
the number of lesions had no impact on the complete ab-
lation rate. Complete ablation was achieved in 51 of 64
(79.7%) lesions in the 25 patients with multifocal tumors,
compared with 13 of 20 (65.0%) lesions in the 20 patients
with a single lesion. There was no significant differ-
ence between patients with single or multiple nodules
(P = 0.178) (Table 2).
Survival
During a median follow-up of 30.9 months (range 3–
94 months), 33 patients died from intrahepatic recurrence
and three patients died from non-HCC related causes.age before RFA; C: MRI image after RFA.
Figure 2 Incomplete ablation of HCC. A: CT image before RFA; B and C: MRI image after RFA.
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with 1-, 2- and 3-year overall survival rates of 89%, 61%,
and 43%, respectively (Figure 3A).
Complications
Two of 45 patients (4.4%) developed procedure-related
major complications after RFA (one with local skin
heat injury and one with gastrointestinal bleeding). No
procedure-related deaths occurred. Minor complications
such as nausea, fever, and post-treatment abdominal pain
were observed in most patients but none required medical
intervention.
Prognostic factors
The prognostic factors used for univariate analysis included
the variables of demographics, liver function, and tumor-
related characteristics. Significant prognostic factors are
shown in Table 3 and Figure 3.
Multivariate analysis confirmed that tumor diameter
(P = 0.045, hazard ratio [HR]: 0.228, 95% confidence inter-
val [CI]: 0.054-0.968) and pretreatment serum AFP level
(P = 0.024, HR: 2.239, 95% CI: 1.114-4.500) were inde-
pendent predictors for survival (Table 4).
Discussion
RFA has been widely used as a curative therapy for small
HCC. The overall survival of patients with small HCC
undergoing RFA is similar to that of patients receiving
surgical Resection [8-10,20,21]. In clinical practice it is
rarely possible to achieve complete ablation for tumorsTable 2 Evaluation of factors affecting ablation efficiency
Prognostic factor Local success (CR) P value
Tumor diameter
≤5 cm 86.4% (38/44) 0.022
>5 cm 65.0% (26/40)
Tumor number
Single 65.0% (13/20) 0.178
Multiple 79.7% (51/64)larger than 5 cm because of the limitation of the ablation
zone [22,23]. For patients with tumors beyond the Milan
criteria, surgical treatment could be another curative
option. If the tumor cannot be completely removed,
palliative TACE treatment is the main treatment of choice.
However, the long-term outcome for patients with unre-
sectable HCC treated with TACE is unsatisfactory due to
the inability to achieve complete tumor necrosis. Repeated
TACE is often needed to completely eradicate the residual
tumors, but its efficiency is limited and the rate of tumor
recurrence or relapse after initial remission or stable
disease is very high.
Several lines of evidence have indicated the feasibility
and benefit of combination therapy of TACE and RFA.
Buscarini et al. treated 14 HCC patients (with lesion size
ranging from 3.8-6.8 cm, median 5.2 cm) with TACE
followed by RFA. Their results suggested the possibility
of treating large HCC with this procedure [24]. Lencioni
et al. similarly reported a successful outcome (82%) among
patients with HCC (lesion size ranging between 3.8 and
8.5 cm) who were treated with TACE prior to RFA [25].
Consistent with previous studies, the post-treatment CR
rate of 76.2% and partial response rate of 23.8% in the
present series indicate an encouraging benefit for patients
with unresectable HCC beyond the Milan criteria.
RFA treatment following TACE has some advantages
over TACE alone. Embolization during the TACE pro-
cedure can block arterial flow, which may reduce heat-sink
effects during RFA thus increasing the volume of the zone
of ablation and reducing the chance of tumor recurrence.
TACE can also control or eliminate micro-metastasis,
which cannot always be detected by ultrasonography, CT,
or MRI. Thus, the addition of TACE may decrease the
chance of micro-metastasis after RFA treatment in HCC
patients with unresectable tumors beyond the Milan
criteria.
With respect to prognostic factors correlated with local
ablation efficiency, our results suggested that lesion diam-
eter (< 50 mm vs. ≥ 50 mm) was statistically significant for
predicting complete ablation (86.4% vs. 65%, P = 0.022).
Figure 3 Survival curves of patients treated with RFA after first-line treatment with TACE. A: Overall cumulative survival of 45 patients
treated with RFA after first-line treatment with TACE; B: Cumulative survival according to AFP level; C: Cumulative survival according to tumor size.
Table 3 Univariate analysis of prognostic factors in
patients treated with RFA after first-line treatment with
TACE
Variable No. of patients (%) OS (months) P value
Age (years)
≥60 18 (40) 34 0.708
<60 27 (60) 27
Gender
Male 39 (86.7) 34 0.388
Female 6 (13.3) 20
AFP
≥400 ng/ml 20 (44.4) 20 0.015
<400 ng/ml 25 (55.6) 43
Lesion size
≥50 mm 41 (91.1) 41 0.028
<50 mm 4 (8.9) 22
Lesion number
Single 10 (22.2) 29 0.888
Multiple 35 (77.8) 28
ALT
≥75 U/L 9 (20.0) 38 0.828
<75 U/L 36 (80.0) 42
GGT
≥100 U/L 21 (46.7) 34 0.869
<100 U/L 24 (53.3) 27
ALB
≥35 g/L 38 (84.4) 34 0.078
<35 g/L 7 (15.6) 20
PT
≥13 s 7 (15.6) 20 0.059
<13 s 38 (84.4) 34
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affect complete ablation, although this might be because
the number of nodules was confined to five in our study.
It is difficult to completely destroy tumors larger than
5 cm by RFA despite multiple overlapping ablations;
however, first-line TACE treatment might reduce the
volume of viable tumor thus making complete ablation
of the lesions possible. This treatment advantage was also
proposed by Vogl, who suggested that repeated TACE
might reduce the size of the treated lesions [26].
In this study, the 1-, 2-, and 3-year survival rates were
89%, 61%, and 43%, respectively. These rates are consistent
with those of other studies. Veltri reported 1- and 2-year
survival rates of 89.7% and 67.1% for TACE-RFA combined
therapy for unresectable non-early HCC (size 30–80 mm,
mean 48.9 mm) [27]. Similarly, Liao et al. [28] adminis-
trated TACE followed by RFA in the treatment of unre-
sectable HCC (size 30–120 mm, mean 58.9 mm) with
1-, 2- and 3-year survival rates of 84%, 57%, and 38%,
respectively. Our multivariate analysis showed that tumor
size and serum AFP level before treatment were prognostic
factors for overall survival. A high pretreatment level of
AFP has previously been reported to be associated with
poorer survival, reflecting not only tumor cell proliferation
but also active disease with continuous necrosis and
regeneration [29,30].
We found that TACE-RFA combined therapy had a
low rate of major complications. No permanent adverse
sequelae or treatment-related deaths were observed. Thus,
combination therapy of TACE followed by RFA appears to
be relatively safe.Table 4 Multivariate analysis of prognostic factors in
patients with RFA after first-line treatment with TACE
Variable P value RR 95% CI
AFP 0.024 2.239 1.114-4.500
Tumor size 0.045 0.228 0.054-0.968
Tumor number 0.565 0.775 0.325-1.848
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In conclusion, our results indicate that combination
therapy of TACE with RFA is safe and effective, and can
achieve a favorable long-term outcome in unresectable
HCC beyond the Milan criteria. The major limitation of
this study was its retrospective nature and non-randomized
design. Further prospective randomized studies are war-
ranted to confirm the efficacy of this promising combin-
ation therapy.
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